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BACKGROUND 
• Pros tati c uret hral lif t procedure (UroLif t) was FDA-approved in
2013 to be used in treatment of benign prostatic hyperplasia. 
• Promising alternative to the TURP demonstrating equivocal
efficacy with markedly reduced recovery time and relatively rapid
improvement of lower urinary tract symptoms (LUTS).
• The 5-year L.I.F.T. study is by far the most robust UroLift
research published to-date, which reported on a prospective
randomized controlled study of 206 subjects.3
• L.I.F.T. study reported stable improvement in the vast majority of
patients over 5 years including preserved uroflow improvement
from initial post-op evaluation and just 13.6% requiring surgical
retreatment. Despite the procedure’s ostensibly high efficacy,
more research is needed on a larger scale.
• Urologists who have received a high level of training on the 
procedure are designated as a “Center of Excellence” (COE).5
These physicians must meet several benchmarks to be given
this designation, including:
• Completion of 60 UroLift cases within 12-month period.5
• Submission of data from a minimum of 30 cases showing
a 40% average improvement in post-op IPSS from pre-op
baseline.5
• A comprehensive literature review yielded just one article about
a single center/surgeon’s experience with UroLift performed on 
just 11 patients.1 
Our group aimed to evaluate the efficacy of Urolift from a 
single-surgeon designated as Center of Excellence 
over a 5-year period. 
METHODS 
A retrospective EMR review was completed for all patients who 
underwent the UroLift procedure by this single center of excellence 
from 2016-2020.  Relevant data points were transferred to a HIPPA 
compliant spreadsheet for a comprehensive statistical analysis.  
Patients who sought further surgical intervention or failed to
achieve an improvement > 10% were classified as a treatment 
failure after 6 months.  
https://www.urolift.com 
RESULTS 
Variable N Mean p-value 
Pre-o IPSS 21.14 <0.0001 
171 11.18 Post-o IPSS 
Reduction in IPSS 47.09¾ 
Overall Pre-o PVR eel 169.38 0.1881 
PVR!ccl 167 Post-o 78.99 
Reduction in PVR 53.36¾ 
Avera e A e ears 239 71.38 
Prostate Volume (gr ams) 42.66 
-l!:fi-11 
Patient Name: Date of birth: ____ Date completed __ _ -----------
Less t han Less than 
About 
More In the past Not at Half Almost Your 
1 iu 5 Half the than Half 
month: All the Always Times Time the Time score 
Time 
1. Incomplete Emptying 
How often have you had the 0 1 2 3 4 5 sensation of not emptying 
your bladder? 
2. Frequency 
How often have you had to 0 1 2 3 4 5 urinate less than every two 
hours? 
3. lntermittency 
How often have you found 
you stopped and started again 0 1 2 3 4 5 
several times when you 
urinated? 
4. Urgency 
How often have you found it 0 1 2 3 4 5 difficult to postpone 
urination? 
5. Weak Stream 
How often have you had a 0 1 2 3 4 5 
weak urinary stream? 
6. Straining 
How often have you had to 0 1 2 3 4 5 
strain to start wination? 
None 1 Time 2 Times 3 Ti.mes 4 Times 5 Times 
7. Nocturia 
How many times did you 



























Score: 1-7: Mild 8-19: Moderate 20-35: Severe 
CONCLUSIONS 
Our research affirms that the UroLift procedure remains an 
excellent surgical option for the management of BPH in qualified 
patients as observed by statistically significant, consistent and 
robust improvements in IPSS quality-of-life metrics.  
Further research is needed to determine any statistically significant 
correlations among patients who did not achieve treatment 
success. Additional analysis may be considered to stratify certain 
aspects of the IPSS amongst studied patients.      
https://www.urolift.com 
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